Back to search results

Long COVID Study: Valacyclovir, Celecoxib, and Paxlovid

This study is testing if a combination of three existing medications—valacyclovir, celecoxib, and Paxlovid—can help reduce symptoms for adults with Long COVID. You might be eligible if you are between 18 and 65 years old and have been diagnosed with Long COVID. The study will compare the effects of these drugs to a placebo (an inactive substance) to see if they improve your overall health and well-being. Researchers will measure success by looking at changes in your self-reported health status over about five months. The study plans to enroll 150 participants, but its current recruitment status is unclear.

Study design
This is a randomized, double-blind study comparing the drug combination to a placebo in 150 adults with Long COVID.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for about 20 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07597902

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

Not Yet Recruiting
PHASE2Ages 18–65InterventionalTreatment
Icahn School of Medicine at Mount Sinai
~150 participants
Updated 2026-05-19 on ClinicalTrials.gov
What's tested:ValacyclovirCelecoxibPaxlovidPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
EQ-5D-5L Visual Analogue Scale (VAS)
Measured over Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

Conditions

Post-acute Sequelae of COVID-19
Long COVID

Explore related trials

Post-Acute Sequelae of COVID-19

NCT07597902

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)

    New York, New Yorkstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Putrino, PhD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

David Putrino, PhD
[email protected]
212-241-7658
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-65 years of age at the time of study entry
Diagnosed with Long COVID
Individuals of child-bearing potential must have a negative serum pregnancy test at screening and agree to on-site urine pregnancy testing at all subsequent study visits
A urine drug screen performed at the Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed amphetamines and opioids/opiates.
Those with mild to moderate depression should be clinically stable for three months, without risk of suicidal ideation or behavior.

Exclusion

Breastfeeding, pregnant, or planning to become pregnant during the next six months.
In the opinion of the Investigator, any clinically significant, uncontrolled, or unstable medical or surgical condition that could affect the individual's ability to participate in the study or potentially compromise their well-being while enrolled in the study.
In the opinion of the Investigator or based on results of the HADS, evidence of a clinically significant psychiatric disorder, e.g., severe, unstable or poorly controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe alcohol use disorder; substance use disorder other than mild cannabis use disorder; or any history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder.
Currently meeting criteria for ME/CFS at the pre-screening or screening visit, or a prior confirmed diagnosis of ME/CFS within the last 5 years. This may be determined as part of the initial screening call or visit.
Any anticipated need for surgery that in the opinion of the Principal Investigator or Sub-I might confound results or interfere with the participant's ability to comply with the protocol.
Symptomatic and/or otherwise clinically significant cardiac disease
Acute non-COVID systemic infection (e.g., HIV, hepatitis) or other active viral or bacterial infection during the screening/washout period or at the Baseline visit.
Currently receiving chronic systemic corticosteroids (\>5 mg prednisone daily, or equivalent)
Routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid, phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Participants on these medications should not be screened.
Uncontrolled sleep apnea.
Use of chronic nucleoside analog antiviral suppression therapy within one month of the Screening Visit or requiring on average more than one acute treatment course every two months.
Current use of celecoxib either alone or in combination with valacyclovir or famciclovir
In the opinion of the Investigator, evidence of current drug or alcohol abuse or dependency, or history of abuse or dependence during the preceding 12 months.
The participant has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y or other bypass procedure).
Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel movements.

What this trial measures

  • EQ-5D-5L Visual Analogue Scale (VAS)Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.